Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 21 (9) , 1043-1047
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Clinical genome sequencing and population preferences for information about ‘incidental’ findings—From medically actionable genes (MAGs) to patient actionable genes (PAGs)PLOS ONE, 2017
- Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized MedicineValue in Health, 2017
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice ExperimentThe Patient - Patient-Centered Outcomes Research, 2016
- Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experimentCanadian Medical Association Journal, 2015
- Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?BMC Medicine, 2014
- Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In BetweenThe American Journal of Human Genetics, 2014
- Genome Medicine: past, present and futureGenome Medicine, 2011
- Evaluating the utility of personal genomic informationGenetics in Medicine, 2009
- Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected childrenClinical Genetics, 2009